A citation-based method for searching scientific literature

Federica Di Nicolantonio, Pietro Paolo Vitiello, Silvia Marsoni, Salvatore Siena, Josep Tabernero, Livio Trusolino, Rene Bernards, Alberto Bardelli. Nat Rev Clin Oncol 2021
Times Cited: 29







List of co-cited articles
117 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


The consensus molecular subtypes of colorectal cancer.
Justin Guinney, Rodrigo Dienstmann, Xin Wang, Aurélien de Reyniès, Andreas Schlicker, Charlotte Soneson, Laetitia Marisa, Paul Roepman, Gift Nyamundanda, Paolo Angelino,[...]. Nat Med 2015
24

Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
Hyuna Sung, Jacques Ferlay, Rebecca L Siegel, Mathieu Laversanne, Isabelle Soerjomataram, Ahmedin Jemal, Freddie Bray. CA Cancer J Clin 2021
24

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.
E Van Cutsem, A Cervantes, R Adam, A Sobrero, J H Van Krieken, D Aderka, E Aranda Aguilar, A Bardelli, A Benson, G Bodoky,[...]. Ann Oncol 2016
20

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer.
Scott Kopetz, Axel Grothey, Rona Yaeger, Eric Van Cutsem, Jayesh Desai, Takayuki Yoshino, Harpreet Wasan, Fortunato Ciardiello, Fotios Loupakis, Yong Sang Hong,[...]. N Engl J Med 2019
483
20

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
20

Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
Thierry André, Kai-Keen Shiu, Tae Won Kim, Benny Vittrup Jensen, Lars Henrik Jensen, Cornelis Punt, Denis Smith, Rocio Garcia-Carbonero, Manuel Benavides, Peter Gibbs,[...]. N Engl J Med 2020
503
20

Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study.
Michael J Overman, Ray McDermott, Joseph L Leach, Sara Lonardi, Heinz-Josef Lenz, Michael A Morse, Jayesh Desai, Andrew Hill, Michael Axelson, Rebecca A Moss,[...]. Lancet Oncol 2017
20

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
Axel Grothey, Eric Van Cutsem, Alberto Sobrero, Salvatore Siena, Alfredo Falcone, Marc Ychou, Yves Humblet, Olivier Bouché, Laurent Mineur, Carlo Barone,[...]. Lancet 2013
17

Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study.
Josep Tabernero, Axel Grothey, Eric Van Cutsem, Rona Yaeger, Harpreet Wasan, Takayuki Yoshino, Jayesh Desai, Fortunato Ciardiello, Fotios Loupakis, Yong Sang Hong,[...]. J Clin Oncol 2021
58
13

Colorectal cancer.
Evelien Dekker, Pieter J Tanis, Jasper L A Vleugels, Pashtoon M Kasi, Michael B Wallace. Lancet 2019
13


Cancer Statistics, 2021.
Rebecca L Siegel, Kimberly D Miller, Hannah E Fuchs, Ahmedin Jemal. CA Cancer J Clin 2021
13

BRAF mutation in metastatic colorectal cancer.
Jolien Tol, Iris D Nagtegaal, Cornelis J A Punt. N Engl J Med 2009
376
10

Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer.
Rodrigo Dienstmann, Louis Vermeulen, Justin Guinney, Scott Kopetz, Sabine Tejpar, Josep Tabernero. Nat Rev Cancer 2017
401
10

Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
G Argilés, J Tabernero, R Labianca, D Hochhauser, R Salazar, T Iveson, P Laurent-Puig, P Quirke, T Yoshino, J Taieb,[...]. Ann Oncol 2020
192
10

Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.
Ryan B Corcoran, Chloe E Atreya, Gerald S Falchook, Eunice L Kwak, David P Ryan, Johanna C Bendell, Omid Hamid, Wells A Messersmith, Adil Daud, Razelle Kurzrock,[...]. J Clin Oncol 2015
302
10

Immunotherapy in colorectal cancer: rationale, challenges and potential.
Karuna Ganesh, Zsofia K Stadler, Andrea Cercek, Robin B Mendelsohn, Jinru Shia, Neil H Segal, Luis A Diaz. Nat Rev Gastroenterol Hepatol 2019
451
10


Heterogeneity in Colorectal Cancer: A Challenge for Personalized Medicine?
Chiara Molinari, Giorgia Marisi, Alessandro Passardi, Laura Matteucci, Giulia De Maio, Paola Ulivi. Int J Mol Sci 2018
85
10

Non-V600 BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer.
Jeremy C Jones, Lindsay A Renfro, Humaid O Al-Shamsi, Alexa B Schrock, Andrew Rankin, Ben Y Zhang, Pashtoon M Kasi, Jesse S Voss, Alexis D Leal, James Sun,[...]. J Clin Oncol 2017
173
10

Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer.
Michael J Overman, Sara Lonardi, Ka Yeung Mark Wong, Heinz-Josef Lenz, Fabio Gelsomino, Massimo Aglietta, Michael A Morse, Eric Van Cutsem, Ray McDermott, Andrew Hill,[...]. J Clin Oncol 2018
912
10

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.
Anirudh Prahallad, Chong Sun, Sidong Huang, Federica Di Nicolantonio, Ramon Salazar, Davide Zecchin, Roderick L Beijersbergen, Alberto Bardelli, René Bernards. Nature 2012
10

Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer.
Ryan B Corcoran, Thierry André, Chloe E Atreya, Jan H M Schellens, Takayuki Yoshino, Johanna C Bendell, Antoine Hollebecque, Autumn J McRee, Salvatore Siena, Gary Middleton,[...]. Cancer Discov 2018
278
10

Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406).
Scott Kopetz, Katherine A Guthrie, Van K Morris, Heinz-Josef Lenz, Anthony M Magliocco, Dipen Maru, Yibing Yan, Richard Lanman, Ganiraju Manyam, David S Hong,[...]. J Clin Oncol 2021
59
10

Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.
Aurélien Marabelle, Marwan Fakih, Juanita Lopez, Manisha Shah, Ronnie Shapira-Frommer, Kazuhiko Nakagawa, Hyun Cheol Chung, Hedy L Kindler, Jose A Lopez-Martin, Wilson H Miller,[...]. Lancet Oncol 2020
540
10

Randomized trial of TAS-102 for refractory metastatic colorectal cancer.
Robert J Mayer, Eric Van Cutsem, Alfredo Falcone, Takayuki Yoshino, Rocio Garcia-Carbonero, Nobuyuki Mizunuma, Kentaro Yamazaki, Yasuhiro Shimada, Josep Tabernero, Yoshito Komatsu,[...]. N Engl J Med 2015
678
10

Clinical Practice Use of Liquid Biopsy to Identify RAS/BRAF Mutations in Patients with Metastatic Colorectal Cancer (mCRC): A Single Institution Experience.
Pietro Paolo Vitiello, Vincenzo De Falco, Emilio Francesco Giunta, Davide Ciardiello, Claudia Cardone, Pasquale Vitale, Nicoletta Zanaletti, Carola Borrelli, Luca Poliero, Marinella Terminiello,[...]. Cancers (Basel) 2019
18
16

Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial.
Erika Martinelli, Giulia Martini, Vincenzo Famiglietti, Teresa Troiani, Stefania Napolitano, Filippo Pietrantonio, Davide Ciardiello, Marinella Terminiello, Carola Borrelli, Pietro Paolo Vitiello,[...]. JAMA Oncol 2021
19
15

Epigenetics of colorectal cancer: biomarker and therapeutic potential.
Gerhard Jung, Eva Hernández-Illán, Leticia Moreira, Francesc Balaguer, Ajay Goel. Nat Rev Gastroenterol Hepatol 2020
199
10

Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer.
A B Schrock, C Ouyang, J Sandhu, E Sokol, D Jin, J S Ross, V A Miller, D Lim, I Amanam, J Chao,[...]. Ann Oncol 2019
209
10

Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA.
Alain R Thierry, Florent Mouliere, Safia El Messaoudi, Caroline Mollevi, Evelyne Lopez-Crapez, Fanny Rolet, Brigitte Gillet, Celine Gongora, Pierre Dechelotte, Bruno Robert,[...]. Nat Med 2014
439
10

Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial.
Chiara Cremolini, Daniele Rossini, Emanuela Dell'Aquila, Sara Lonardi, Elena Conca, Marzia Del Re, Adele Busico, Filippo Pietrantonio, Romano Danesi, Giuseppe Aprile,[...]. JAMA Oncol 2019
130
10

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.
Dung T Le, Jennifer N Uram, Hao Wang, Bjarne R Bartlett, Holly Kemberling, Aleksandra D Eyring, Andrew D Skora, Brandon S Luber, Nilofer S Azad, Dan Laheru,[...]. N Engl J Med 2015
10

The molecular profiling of solid tumors by liquid biopsy: a position paper of the AIOM-SIAPEC-IAP-SIBioC-SIC-SIF Italian Scientific Societies.
A Russo, L Incorvaia, M Del Re, U Malapelle, E Capoluongo, V Gristina, M Castiglia, R Danesi, M Fassan, G Giuffrè,[...]. ESMO Open 2021
26
11

Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.
Andrea Sartore-Bianchi, Livio Trusolino, Cosimo Martino, Katia Bencardino, Sara Lonardi, Francesca Bergamo, Vittorina Zagonel, Francesco Leone, Ilaria Depetris, Erika Martinelli,[...]. Lancet Oncol 2016
496
6

Colorectal Cancer Consensus Molecular Subtypes Translated to Preclinical Models Uncover Potentially Targetable Cancer Cell Dependencies.
Anita Sveen, Jarle Bruun, Peter W Eide, Ina A Eilertsen, Lorena Ramirez, Astrid Murumägi, Mariliina Arjama, Stine A Danielsen, Kushtrim Kryeziu, Elena Elez,[...]. Clin Cancer Res 2018
118
6

Phase II Study of Tivantinib and Cetuximab in Patients With KRAS Wild-type Metastatic Colorectal Cancer With Acquired Resistance to EGFR Inhibitors and Emergence of MET Overexpression: Lesson Learned for Future Trials With EGFR/MET Dual Inhibition.
Lorenza Rimassa, Silvia Bozzarelli, Filippo Pietrantonio, Stefano Cordio, Sara Lonardi, Laura Toppo, Alberto Zaniboni, Roberto Bordonaro, Maria Di Bartolomeo, Gianluca Tomasello,[...]. Clin Colorectal Cancer 2019
27
7

Molecular characterization of colorectal cancer patients and concomitant patient-derived tumor cell establishment.
Haa-Na Song, Chung Lee, Seung Tae Kim, Sun Young Kim, Nayoung K D Kim, Jiryeon Jang, Mihyun Kang, Hyojin Jang, Soomin Ahn, Seok Hyeong Kim,[...]. Oncotarget 2016
11
18

Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial.
Andrea Sartore-Bianchi, Sara Lonardi, Cosimo Martino, Elisabetta Fenocchio, Federica Tosi, Silvia Ghezzi, Francesco Leone, Francesca Bergamo, Vittorina Zagonel, Fortunato Ciardiello,[...]. ESMO Open 2020
36
6

Comprehensive review of targeted therapy for colorectal cancer.
Yuan-Hong Xie, Ying-Xuan Chen, Jing-Yuan Fang. Signal Transduct Target Ther 2020
295
6

A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.
Andrea Bertotti, Giorgia Migliardi, Francesco Galimi, Francesco Sassi, Davide Torti, Claudio Isella, Davide Corà, Federica Di Nicolantonio, Michela Buscarino, Consalvo Petti,[...]. Cancer Discov 2011
601
6

HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer.
Andrea Sartore-Bianchi, Alessio Amatu, Luca Porcu, Silvia Ghezzi, Sara Lonardi, Francesco Leone, Francesca Bergamo, Elisabetta Fenocchio, Erika Martinelli, Beatrice Borelli,[...]. Oncologist 2019
43
6

Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer.
Giulia Siravegna, Luca Lazzari, Giovanni Crisafulli, Andrea Sartore-Bianchi, Benedetta Mussolin, Andrea Cassingena, Cosimo Martino, Richard B Lanman, Rebecca J Nagy, Stephen Fairclough,[...]. Cancer Cell 2018
76
6

Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study.
Funda Meric-Bernstam, Herbert Hurwitz, Kanwal Pratap Singh Raghav, Robert R McWilliams, Marwan Fakih, Ari VanderWalde, Charles Swanton, Razelle Kurzrock, Howard Burris, Christopher Sweeney,[...]. Lancet Oncol 2019
178
6

Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients.
Salo N Ooft, Fleur Weeber, Krijn K Dijkstra, Chelsea M McLean, Sovann Kaing, Erik van Werkhoven, Luuk Schipper, Louisa Hoes, Daniel J Vis, Joris van de Haar,[...]. Sci Transl Med 2019
222
6

NTRK gene fusions as novel targets of cancer therapy across multiple tumour types.
Alessio Amatu, Andrea Sartore-Bianchi, Salvatore Siena. ESMO Open 2016
295
6

A genetic model for colorectal tumorigenesis.
E R Fearon, B Vogelstein. Cell 1990
6

Class 1, 2, and 3 BRAF-Mutated Metastatic Colorectal Cancer: A Detailed Clinical, Pathologic, and Molecular Characterization.
Marta Schirripa, Paola Biason, Sara Lonardi, Nicoletta Pella, Maria Simona Pino, Federica Urbano, Carlotta Antoniotti, Chiara Cremolini, Salvatore Corallo, Filippo Pietrantonio,[...]. Clin Cancer Res 2019
30
6

Response to Anti-EGFR Therapy in Patients with BRAF non-V600-Mutant Metastatic Colorectal Cancer.
Rona Yaeger, Daisuke Kotani, Sebastián Mondaca, Aparna R Parikh, Hideaki Bando, Emily E Van Seventer, Hiroya Taniguchi, HuiYong Zhao, Claire N Thant, Elisa de Stanchina,[...]. Clin Cancer Res 2019
37
6

EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib.
Ryan B Corcoran, Hiromichi Ebi, Alexa B Turke, Erin M Coffee, Michiya Nishino, Alexandria P Cogdill, Ronald D Brown, Patricia Della Pelle, Dora Dias-Santagata, Kenneth E Hung,[...]. Cancer Discov 2012
646
6


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.